Investment Rating - The investment rating for the company is "Accumulate" [8] Core Views - The company is expected to recover its performance in 2025 driven by new products and overseas expansion [1][2] - Despite a decline in revenue and profit in Q1 2025 due to high base effects, there is optimism for growth throughout the year as demand recovers and channels expand [1][2] Revenue and Profit Analysis - In 2024, the company's revenue was 7.566 billion yuan, a year-on-year decrease of 5.09%, while the net profit attributable to the parent company was 1.806 billion yuan, down 24.63% [1] - Q4 2024 showed a revenue of 1.538 billion yuan, a year-on-year increase of 17.51%, and a net profit of 274 million yuan, up 33.60% [1] - For Q1 2025, revenue reached 2.436 billion yuan, a year-on-year increase of 9.17%, while net profit was 625 million yuan, down 5.26% [1] Product and Channel Growth - The blood glucose and AED new products are expected to drive high growth in revenue [3] - The blood glucose management segment saw a 40% year-on-year revenue increase in 2024, with CGM products experiencing over 100% growth [3] - The overseas revenue for 2024 was 949 million yuan, a year-on-year increase of 30%, indicating significant growth potential in international markets [4] Profitability Outlook - The gross margin for 2024 was 50.14%, a slight decrease of 1.35 percentage points year-on-year, but is expected to maintain a relatively high level in 2025 [5] - The net margin for 2024 was 23.85%, down 5.96 percentage points year-on-year, but is projected to remain high due to cost reduction and efficiency improvements [5] Financial Forecast and Valuation - Revenue projections for 2025-2027 are 8.688 billion, 10.056 billion, and 11.543 billion yuan, representing year-on-year growth rates of 14.83%, 15.75%, and 14.78% respectively [6] - Net profit forecasts for the same period are 2.094 billion, 2.423 billion, and 2.798 billion yuan, with corresponding year-on-year growth rates of 15.95%, 15.75%, and 15.46% [6]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company has faced significant revenue and profit declines in 2024, with operating income of 36.441 billion yuan, down 40.72% year-on-year, and a net profit of 2.961 billion yuan, down 42.60% year-on-year [20][14] - Despite the challenges, the company remains optimistic about its coal transportation business in Xinjiang, which is expected to recover due to seasonal demand [14] Summary by Sections Overall Performance - In 2024, the company reported an operating income of 36.441 billion yuan, a decrease of 40.72% year-on-year, and a net profit of 2.961 billion yuan, down 42.60% year-on-year. The net cash flow from operating activities was 5.675 billion yuan, down 16.64% year-on-year [20][14] Coal Business - The coal business achieved record production and sales, with raw coal output reaching 39.8329 million tons, up 78.52% year-on-year, and total coal sales of 47.234 million tons, up 52.39% year-on-year. Revenue from coal operations was 17.379 billion yuan, an increase of 18.03% year-on-year, although the gross margin fell to 22.95%, down 11.73 percentage points due to declining sales prices [27][29] Natural Gas Business - The company reduced its external gas procurement due to price discrepancies, resulting in a 51.65% year-on-year decrease in external LNG sales to 2.2393 million tons. Total natural gas sales were 2.8401 million tons, down 52.95% year-on-year. Revenue from natural gas sales dropped to 13.065 billion yuan, down 65.95% year-on-year, while the gross margin improved to 14.37%, up 6.26 percentage points [31][33] Coal Chemical Business - The coal chemical segment maintained stable production, with methanol output of 1.0788 million tons, up 18.43% year-on-year, and ethylene glycol output of 155,600 tons, up 23.73% year-on-year. However, total sales in this segment decreased by 8.42% year-on-year [36][39] Profit Forecast and Valuation - The company forecasts a net profit of 3.487 billion yuan for 2025, reflecting a 17.75% increase year-on-year, with expected earnings per share of 0.54 yuan. The company is positioned well in Xinjiang with strong coal reserves and advanced production capacity, indicating potential for valuation recovery [14][42]

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Views - The company's performance in Q1 2025 met expectations, with a significant year-on-year increase in net profit of 180.99% [1][2] - The shipbuilding industry is experiencing an upward cycle due to factors such as the ship replacement cycle, environmental policies, and tight production capacity [4][5] - The company has a strong order backlog, with a total of 2,169.62 billion yuan in hand for civil ship orders as of 2024 [2] Financial Performance - In 2024, the company achieved an operating revenue of 78,584 million yuan, a year-on-year increase of 5.01%, and a net profit attributable to shareholders of 3,614 million yuan, up 22.21% [1] - For Q1 2025, the company reported an operating revenue of 15,858 million yuan, a 3.85% increase year-on-year, and a net profit of 1,127 million yuan, reflecting a 180.99% increase [2] - The gross profit margin for 2024 was approximately 10.20%, with a net profit margin of 4.91% [3] Business Segmentation - The shipbuilding and marine engineering segment generated revenue of 75,374 million yuan in 2024, up 7.03% year-on-year [1] - The electromechanical equipment segment reported revenue of 1,956 million yuan, a 1.45% increase [1] - The company delivered 93 civil ships in 2024, achieving 721.34 million deadweight tons, exceeding the annual plan by 112.74% [2] Order and Delivery Insights - The company secured new orders worth 1,039 million yuan for civil ships in 2024, along with 20.73 million yuan for repair services [1] - As of Q1 2025, the company’s gross profit margin improved to 12.84%, a year-on-year increase of 5.62 percentage points [3] - The total hand-held civil ship orders amounted to 2,169.62 billion yuan, indicating strong future revenue potential [2] Industry Trends - The shipbuilding industry is witnessing a slowdown in new orders, with a 56% year-on-year decline in new orders from January to April 2025 [4][17] - Despite the slowdown, ship prices are expected to continue rising due to tight supply and inflationary pressures [4][5] - The integration of shipbuilding assets within the group is progressing smoothly, which is expected to enhance operational efficiency and competitive positioning [5]

证券研究报告 | 浙商早知道 报告日期：2025 年 05 月 16 日 浙商早知道 2025 年 05 月 16 日 ： 张延兵 执业证书编号：S1230511010020 ： 021-80106048 ： zhangyanbing@stocke.com.cn 市场总览 ❑ 资金：周四沪深两市总成交额为 11524 亿元，南下资金净流出 2,21 亿港元。 浙商早报 1 市场总览 1、大势：周四上证指数下跌 0.7%，沪深 300 下跌 0.9%，科创 50 下跌 1.3%，中证 1000 下跌 1.7%，创 业板指下跌 1.9%，恒生指数下跌 0.8%。 重要观点 ❑ 【浙商宏观 李超/费瑾】宏观专题研究：4 月金融数据：金融数据回落中的结构性亮点——20250514 重要点评 ❑ 【浙商大制造中观策略 邱世梁/王华君/张菁】机械设备 行业深度：深海科技：政策东风起，聚焦深海装备、深 海信息技术、深海探测等——20250514 http://www.stocke.com.cn 1/4 请务必阅读正文之后的免责条款部分 ❑ 大势：周四上证指数下跌 0.7%，沪深 300 下跌 0.9%，科创 50 下跌 1 ...

Investment Rating - The investment rating for Zhengmei Machine (601717) is "Accumulate" [4] Core Views - The company achieved a total operating revenue of 37.05 billion yuan in 2024, representing a year-on-year growth of 1.7%. The net profit attributable to shareholders was 3.93 billion yuan, up 20.2%, driven by revenue structure optimization in the coal machinery segment and a decrease in material costs [2][10] - In Q1 2025, the company reported an operating revenue of 9.76 billion yuan, a 0.9% increase year-on-year, and a net profit of 1.09 billion yuan, reflecting a 4.5% year-on-year growth, mainly due to the growth of the automotive parts subsidiary Yaxin Technology and increased shareholding in subsidiaries [2] - The company's profitability showed slight fluctuations, with a decrease in expense ratios and significant cost reduction and efficiency improvement effects [2] Financial Performance Summary - For 2024, the gross profit margin was 24.0%, an increase of 1.9 percentage points year-on-year, while the net profit margin was 11.4%, also up by 1.9 percentage points year-on-year. In Q1 2025, the gross profit margin was 23.5%, down 0.4 percentage points year-on-year, and the net profit margin was 11.5%, down 0.7 percentage points year-on-year [2][3][15] - The company’s expense ratio for 2024 was 10.9%, a decrease of 0.5 percentage points year-on-year, with sales expense ratio at 2.5%, down 0.6 percentage points, and R&D expense ratio at 4.1%, down 0.2 percentage points [3][15] Profit Forecast - The company is expected to achieve operating revenues of 38.2 billion yuan, 40.2 billion yuan, and 43.9 billion yuan for 2025, 2026, and 2027 respectively, with a compound annual growth rate (CAGR) of 7%. The net profit attributable to shareholders is projected to be 4.11 billion yuan, 4.41 billion yuan, and 4.99 billion yuan for the same years, with a CAGR of 10% [4][5]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is entering a realization phase for its biopharmaceuticals, with expectations of an upward turning point [1] - The company achieved a revenue of 3.924 billion yuan in 2024, a slight decrease of 0.20% year-over-year, while the net profit attributable to shareholders increased significantly by 536.09% to 826 million yuan [1][9] - The first quarter of 2025 saw a revenue of 885 million yuan, down 11.85% year-over-year, and a net profit of 85 million yuan, down 52.19% year-over-year [1] Revenue and Profitability - The company's revenue from non-heparin formulations is expected to drive growth in overseas formulations, with a projected revenue of 3.050 billion yuan from formulations in 2024, representing a year-over-year increase of 10.05% [1][2] - The revenue from non-heparin formulations reached 1.467 billion yuan in 2024, showing a year-over-year growth of 24.25% [1][2] - The company’s heparin raw material revenue is declining, with a projected revenue of 787 million yuan in 2024, accounting for 20.06% of total revenue [2] Future Growth Drivers - The company is expected to see significant growth from its high-margin biopharmaceutical product line, which is entering a realization phase [2][3] - The company has received FDA approvals for several products, including Liraglutide in April 2025, which is anticipated to enhance its international market presence [1][2] Financial Forecasts - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 0.65 yuan, 0.90 yuan, and 1.22 yuan respectively [3][9] - The company’s revenue is expected to grow to 4.785 billion yuan in 2025, representing a year-over-year increase of 21.95% [9] Market Position - The company is successfully transitioning from a traditional raw material supplier to an international sterile injection enterprise, with a focus on quality and cost leadership [2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Insights - The company achieved a revenue of 2.358 billion yuan in 2024, representing a year-on-year growth of 40.29%. Despite the pressure on the cybersecurity industry due to tightened budgets from downstream clients, the company focused on core customers and high-value markets to achieve growth [2] - The company's net loss narrowed to 365 million yuan in 2024, with a significant improvement in operating quality driven by cost reduction and efficiency enhancement strategies. The gross margin for security products reached 67.87% [3] - The company is targeting AI and security as dual engines for growth, with plans to enhance its technology stack and build ecosystems in the future [4] Summary by Sections Financial Performance - In 2024, the company reported a revenue of 2.358 billion yuan, a 40.29% increase year-on-year. The net loss was reduced to 365 million yuan, with a net profit margin improvement from -58.1% to -15.5% [2][3] - For Q4 2024, the revenue was 1.084 billion yuan, showing a year-on-year growth of 128.67% [8] - The company forecasts revenues of 2.536 billion yuan, 2.743 billion yuan, and 2.981 billion yuan for 2025, 2026, and 2027 respectively, with expected net profits turning positive in 2025 [9][10] Strategic Focus - The company is implementing a "focus strategy" to optimize resource allocation, concentrating on stable core customers in sectors like telecommunications, finance, and energy while reducing inefficiencies in other markets [2] - The introduction of a restricted stock incentive plan for 2024 indicates management's confidence in long-term performance improvement, with revenue targets set for 2025 and 2026 [2] Innovation and Market Position - The company made significant advancements in AI and security, launching the "Fengyunwei AI Security Capability Platform" and the "AI-Scan" risk assessment product [4] - The strategic goal is to solidify domestic leadership while expanding into international markets, aiming to become a leader in digital cybersecurity [4]

Investment Rating - The industry investment rating is optimistic [1] Core Viewpoints - The report indicates that the turning point for the CXO sector has emerged, suggesting a positive outlook for investment [6][70] - The report highlights that domestic performance, orders, and AI are the main themes driving growth [5] - The report emphasizes the recovery of revenue growth year-over-year (YOY) and the gradual improvement in profitability [5][29] Summary by Sections Price Review - The medical research outsourcing index increased by 0.82% from December 31, 2024, to April 30, 2025, outperforming the pharmaceutical and biotechnology index by 0.64 percentage points [5] Financial Analysis - Revenue growth is showing a positive trend, with the average YOY revenue growth for CXO companies reaching 8.2% in Q1 2025 [28] - The average gross margin for Q1 2025 is 30.9%, reflecting a YOY increase of 1.1 percentage points [34] - The average net profit margin excluding non-recurring items is 8.0%, up by 12.5 percentage points YOY [34] Growth Potential - The report notes that the global healthcare industry is seeing a stabilization in private equity and venture capital financing, which is expected to drive demand recovery [6] - The report mentions that the order growth for leading companies remains strong, with notable increases in new orders for companies like Kailaiying and Kanglonghua [61] Operational Efficiency - Inventory turnover rates have improved, with an average of 3.36 in 2024, indicating a stabilization in operational efficiency [39] - The report anticipates that operational efficiency will continue to improve as leading CXO companies execute orders and enhance capacity utilization [39] Investment Strategy - The report recommends actively allocating investments in the CXO sector, particularly in small molecule and large molecule CDMO opportunities, as well as clinical CROs supported by domestic innovation policies [72]

Investment Rating - The investment rating for the company is "Buy" [7] Core Views - The company has shown strong performance with a 42% year-on-year increase in net profit attributable to the parent company in Q1 2025, driven by multiple factors including flexible employment growth and recovery in overseas and headhunting services [1][4] - The company is expected to benefit from the increasing demand for high-value technical positions and the recovery of its overseas and headhunting businesses, leading to an upward revision of profit forecasts for 2025 to 2027 [4] Financial Overview - In 2024, the company reported revenues of 11.79 billion with a year-on-year growth of 21%, and a net profit of 205 million, reflecting a 2% increase [1] - For Q1 2025, revenues reached 3.3 billion, marking a 25% increase year-on-year, with a net profit of 57.78 million, up 42% from the previous year [1] - The company’s revenue breakdown for 2024 shows that flexible employment services accounted for 94.5% of total revenue, with a year-on-year growth of 22% [2] Business Segmentation - The flexible employment segment remains the core driver of growth, while headhunting services have shown signs of recovery with a 22% increase in successful placements in Q1 2025 [3] - The company’s overseas revenue has shown a narrowing decline, suggesting a potential turning point in 2025 as management synergies improve [2][3] Profit Forecast and Valuation - The company is projected to achieve net profits of 291 million, 353 million, and 423 million for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 41.93%, 21.11%, and 19.87% [4][6] - The current market valuation corresponds to a price-to-earnings ratio of 20.8X for 2025, 17.2X for 2026, and 14.3X for 2027 [4][6]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company faced a significant decline in revenue, with a 32.49% year-on-year decrease, resulting in a net loss of 1.379 billion yuan in 2024, primarily due to macroeconomic fluctuations and reduced IT budgets from clients [2][9] - Despite short-term revenue pressures, the company is focusing on cash flow optimization, achieving a cash collection ratio of 109.40% and improving operating cash flow by 436 million yuan year-on-year [2] - The company has implemented effective cost control measures, with total expenses decreasing by 12.66% in 2024, and anticipates profit recovery in 2025 as it continues to refine expense management [3] Summary by Sections Financial Performance - In 2024, the company reported total revenue of 4.349 billion yuan, a decrease of 32.49% year-on-year, and a net profit loss of 1.379 billion yuan [9] - The fourth quarter of 2024 saw a revenue of 1.639 billion yuan, down 40.55% year-on-year, with a net profit loss of 203 million yuan [9] - For Q1 2025, the company achieved revenue of 686 million yuan, a slight decline of 2.65%, with a net profit loss of 418 million yuan, indicating a narrowing of losses [9] Strategic Initiatives - The company has introduced a "Four Focus" strategy aimed at steady revenue growth, which includes focusing on core products, key customers, enhancing distributor effectiveness, and expanding into overseas markets [4] - The company plans to leverage AI technologies to enhance its product offerings, particularly in threat detection and security operations [4] Future Outlook - Revenue projections for 2025-2027 are estimated at 4.435 billion, 4.608 billion, and 4.849 billion yuan respectively, with a gradual recovery in net profit expected by 2027 [10] - The company is expected to benefit from improved operational quality and cash flow levels, providing a higher performance elasticity in the long term [10]